Browse studies

Find your next paid study

5 recruiting studies matching your filters

TACTICAL: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT).…

GVHDHematopoietic Cell Transplantation (HCT)Acute Myeloid Leukemia (AML)+4 more

Estimated

~$10 – $6,250

Stanford UniversityNCT07302776

Phase 1

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in co…

Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07128381

Phase 1

A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced …

Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Chronic Myelomonocytic Leukemia-1+9 more

Estimated

~$10 – $8,750

Solu Therapeutics, IncNCT06950034

Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who hav…

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)Acute Leukemia (Category)+8 more

Estimated

~$10 – $7,500

Center for International Blood and Marrow Transplant ResearchNCT06859424

Phase 1

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants …

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT06994676